Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. - Test2 - elhamkhani - TriplyDB

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.

http://www.wikidata.org/entity/Q33548625

about

Structural basis of substrate discrimination and integrin binding by autotaxin Boron chemicals in diagnosis and therapeutics Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling Autotaxin: structure-function and signaling Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest Exocrine pancreatic carcinogenesis and autotaxin expression Expression of LPP3 in Bergmann glia is required for proper cerebellar sphingosine-1-phosphate metabolism/signaling and development A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension The Autotaxin-Lysophosphatidic Acid Axis Modulates Histone Acetylation and Gene Expression during Oligodendrocyte Differentiation Distinct functional and conformational states of the human lymphoid tyrosine phosphatase catalytic domain can be targeted by choice of the inhibitor chemotype.Target highlights in CASP9: Experimental target structures for the critical assessment of techniques for protein structure prediction Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice.Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate.Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration.Mammalian cell expression, purification, crystallization and microcrystal data collection of autotaxin/ENPP2, a secreted mammalian glycoprotein.Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis.Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.Lysophosphatidic acid in atherosclerotic diseases The phospholipase A1 activity of lysophospholipase A-I links platelet activation to LPA production during blood coagulation Integrating chemical and genetic silencing strategies to identify host kinase-phosphatase inhibitor networks that control bacterial infection Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate.Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin Insulin-like growth factor 1 (IGF-1) stabilizes nascent blood vessels Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells.Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution Lysophospholipid mediators in the vasculature Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Ligand-based autotaxin pharmacophore models reflect structure-based docking results.Mitigation of the hematopoietic and gastrointestinal acute radiation syndrome by octadecenyl thiophosphate, a small molecule mimic of lysophosphatidic acid c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas Chemical evolution of autotaxin inhibitors Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.

P2860

Q24337236-1BD7BC6F-CAF1-4B58-8B0E-AD38B70A88FC Q27006075-31125E08-CA04-4818-9B8B-757A02653F93 Q27015257-19D513A7-124D-4579-94E7-ABC546DCAAF1 Q28260852-A3B64864-B941-4109-857E-CDE91F96A9BA Q28274830-D91B340A-72E8-4C7E-BA5A-372D809FE258 Q28307790-AAD44A4B-BD12-48EA-A9E0-1D19ADF85D11 Q28478339-7AE6D99E-0D53-4CB0-9397-8943A568E7BD Q28482954-77858758-2015-41D1-A990-F6552EA538CF Q28508004-4D82E481-589F-402D-A99A-AC8ADCD1EE9B Q28534911-FCF47203-453E-4517-A08E-5642D0FD0684 Q28538027-ADC9469E-F7D2-4082-AB63-CEC761C60ECD Q30360840-8DE570C8-DBA9-4AB5-9D53-8DF2FD66C152 Q30406901-6EEF11AC-8263-4B80-82E6-1F06464126B2 Q30408519-FC6B0696-1D20-4C5A-9076-056D5DED5FC4 Q30410474-88A96B82-A0F5-4CB1-8CF4-8C96D831A737 Q30423337-D428D450-0725-437D-9B25-A30D7FD77E25 Q30429428-6E27622F-25CB-415F-BD2B-49CD7C3846E2 Q30566362-19F0DC91-17A7-4CAA-921B-4C26A051210C Q33686732-E0E91617-A371-4D98-9A3D-4DCB094D8C20 Q33756825-6A539D65-B495-4976-AD42-753917279AB4 Q33832789-595FB315-E5F7-4885-9113-08DB4B06FF54 Q33846709-446E073C-25E4-454D-8983-8AD75FE1FF9D Q34273486-39B97B8A-15B5-445F-B4DA-A3E5B85BD923 Q34776268-A1DD49F2-255A-4BB4-93D5-9909E8D8E1C8 Q35052439-87264FFE-844A-4B2A-AD7A-1B4984D5742A Q35053132-F90A0421-CC24-4E06-B9CF-A5D7184C70A2 Q35118841-28FED5B4-058D-4C0F-86E5-FB5000283A97 Q35172962-F9024559-2246-4C03-AE03-BC4280A624B7 Q35266443-42B759DF-0B6E-4D82-9C2E-149966C2DBD3 Q35314358-91B8CB9E-FE68-4DAF-9733-92C3A85A8B23 Q35533485-109841BF-0527-438F-8373-D0507BC3FD2B Q35551835-BBF53DB1-5796-4401-88A1-DB0F03111127 Q35575527-09778106-79C4-4717-AB47-93CD490F3594 Q35597324-D13171B3-FE24-4959-ACE5-326CDADF33B5 Q35756057-82D213AB-7EF7-4516-A5E6-F1817307865C Q35949924-C8EB66C3-D288-47CD-B21A-808FF668351F Q36011319-6880BDC7-66EB-40F1-B0E3-EAFAE02023E0 Q36399256-61A8240D-DCA3-4764-AA42-7A335D30B724 Q36431033-F99E6397-70A9-4DE0-A311-069E081129A2 Q36452780-216E2919-023C-44BC-8026-72584985DED4

P2860

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.

http://www.wikidata.org/entity/Q33548625

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@ast

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@en

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@nl

type

label

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@ast

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@en

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@nl

prefLabel

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@ast

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@en

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@nl

P1433

Q33548625-C9CD6045-F013-4A96-A068-97124B3B6FDE

P1476

Q33548625-C2080E04-0714-4E6D-996D-4710509EDD38

P2093

Q33548625-38A12024-38B1-4C91-8D2F-EE77B759E4DD

Q33548625-648B8608-0DB7-4742-A794-E7C15ABBDA38

Q33548625-6CC88CD6-B840-4BFD-B6C9-C0705DE8FCB6

Q33548625-7557F146-0824-4D82-8DC0-5B8CB5BC909F

Q33548625-78FFC036-509F-4B68-B93D-A00C91CBA6DC

Q33548625-87D1BC44-4D77-48C5-BDE4-F10C7BCED81B

Q33548625-89375939-490C-4C31-901E-0AC7CFB2AF90

Q33548625-C72519F2-5B29-4849-8114-10C23DB6D983

Q33548625-F60E79E5-5629-493D-8B5D-F661610114B0

P2860

Q33548625-0866D2BB-B669-485F-85CB-6AB268574EE4

Q33548625-10C28816-3280-4877-9E05-27BA8587933A

Q33548625-1628990A-F55D-47B0-ACB1-944A67B2F9EB

Q33548625-1C11969A-5CF1-4B3F-AA59-CA7F916DFA57

Q33548625-1DA9594E-7624-4FB0-8BDD-4C85687E3198

Q33548625-21FF860F-A228-4112-A56C-EA1C63F4F937

Q33548625-298B971E-0032-473B-ADEA-5CF4B9C5E5C5

Q33548625-2FD809C6-B429-412F-8947-011C7D621F1F

Q33548625-358F146B-D063-4E3C-BABD-3D91D84A90C7

Q33548625-3619E767-48D7-4F63-8903-8ADEB0641F84

P304

Q33548625-A4E26277-AB72-4601-8F83-AA4C0D08CB99

P31

Q33548625-E593658E-269B-46C6-80C2-D71C81E910E1

P356

Q33548625-0692AA65-ADBD-47DC-8A9C-AD63FFA80606

P407

Q33548625-A0376314-0DF8-494C-8FCD-9F686F0C047F

P433

Q33548625-683C7DC0-2BCA-46D8-82ED-A5842E2A686F

P478

Q33548625-0E527234-A49B-4EFB-98EE-CC8ADFEDA039

P50

Q33548625-2C4099FA-BB7F-4F50-9AFC-50C9BBCEBD68

Q33548625-2E8B857D-73E3-411E-A662-524FEAF8DEA1

Q33548625-7EA00A95-06CA-4938-987E-A60B4D7959CD

P577

Q33548625-708E9115-A928-443E-AD6B-01725264E595

P5875

Q33548625-0E4CBE58-F041-4C61-8795-16C494CB5E7C

P698

Q33548625-5098B092-9E53-4A27-B6CF-6F2A17F9D895

P932

Q33548625-EE9AB57A-5791-458E-A08C-EAD33110DBC9

P356

PNAS.1001529107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Boronic acid-based inhibitor o ...... ver of LPA in the circulation.

@en

P2093

Andrew J Morris

http://www.w3.org/2001/XMLSchema#string

Anping Dong

http://www.w3.org/2001/XMLSchema#string

David A Egan

http://www.w3.org/2001/XMLSchema#string

Erica W van Tilburg

http://www.w3.org/2001/XMLSchema#string

Harald M H G Albers

http://www.w3.org/2001/XMLSchema#string

Karianne Schuurman

http://www.w3.org/2001/XMLSchema#string

Olaf van Tellingen

http://www.w3.org/2001/XMLSchema#string

Susan S Smyth

http://www.w3.org/2001/XMLSchema#string

Wouter H Moolenaar

http://www.w3.org/2001/XMLSchema#string

P2860

Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein

Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production

The emerging role of lysophosphatidic acid in cancer

Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase

Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate

Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.

alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors

Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.

P304

7257-7262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1001529107

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Laurens A van Meeteren

Manjula Sunkara

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42833788

http://www.w3.org/2001/XMLSchema#string

P698

20360563

http://www.w3.org/2001/XMLSchema#string

P932

2867685

http://www.w3.org/2001/XMLSchema#string